10489620-bd98-43ab-9d5f-8ae0c0b1ff7a
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 68.3367556468173
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.610
- MYC_TARGETS_V2+0.530
- INTERFERON_GAMMA_RESPONSE+0.370
- WNT_BETA_CATENIN_SIGNALING+0.360
- G2M_CHECKPOINT+0.330
- E2F_TARGETS+0.310
- NOTCH_SIGNALING+0.240
- DNA_REPAIR+0.170
- MYC_TARGETS_V1+0.140
- KRAS_SIGNALING_DN+0.100
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.580
- ANGIOGENESIS-0.480
- PROTEIN_SECRETION-0.430
- UV_RESPONSE_DN-0.410
- ANDROGEN_RESPONSE-0.370
- HYPOXIA-0.340
- APOPTOSIS-0.310
- TGF_BETA_SIGNALING-0.310
- APICAL_SURFACE-0.300
- KRAS_SIGNALING_UP-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR33532781 | — | D | 0.795 |
| 2 | TCGA-OL-A5D7-01A-11R-A27Q-07 | — | E | 0.792 |
| 3 | ULC0564T_S96 | — | cohortA1 | 0.780 |
| 4 | TCGA-CV-6936-01A-11R-1915-07 | — | — | 0.777 |
| 5 | SRR1313149 | — | D | 0.775 |
| 6 | SRR2932834 | — | — | 0.772 |
| 7 | SRR650177 | — | — | 0.766 |
| 8 | SRR10900589 | — | — | 0.760 |
| 9 | SRR8613767 | — | E | 0.760 |
| 10 | 90dab784-fa67-4b32-9489-6cd1cb6365ac | — | — | 0.759 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.610 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.530 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.370 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.360 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.330 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.310 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.240 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.140 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.100 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.090 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.090 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.090 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.080 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.020 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.020 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.010 | Idelalisib | — uncovered |